6 news items
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
CADL
23 May 24
-limiting toxicities or grade 4 or higher treatment-related adverse events (TRAEs); the majority of TRAEs were grade 1 or 2, and there were three grade 3
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CADL
20 May 24
-tumor immune response. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells
Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer
CADL
11 Apr 24
, with no dose-limiting toxicities and no cases of pancreatitis. Analysis of resected tumors showed treatment with CAN-2409 modified the tumor
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
CADL
4 Apr 24
toxicities, including no cases of pancreatitis.
Price Action: CADL shares are up 31.70% at $2.21 on the last check Thursday.
Photo via Shutterstock
Candel Therapeutics Announces Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
CADL
4 Apr 24
, providing further support that multiple injections of CAN-2409 were generally well tolerated, with no dose-limiting toxicities and no cases
ndw3c28o3 lsjzb
CADL
15 Mar 24
of all, local delivery enables Candel to achieve these results while aiming to minimize systemic toxicity
- Prev
- 1
- Next